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Nineteen patients completed the study (Table 1) ; there were 12 withdrawals due to adverse events (AEs; n=4; 36%), death (n=2; 18%), transformation to high-grade MDS (n=1; 9%), eligibility criteria (n=1; 9%), withdrawal of consent (n=1; 9%) and unspecified reasons (n=3; 27%). 
n=16; CI, confidence interval; MFC, mean fluorescence channel
The baseline characteristics demonstrate high levels of oxidative stress and iron overload in these transfused patients with MDS; levels of ROS were higher than the normal range, while levels of the antioxidant GSH were lower than normal. These results confirm our previous study, which also showed increased oxidative stress in patients with MDS. 9 Sixteen patients received daily deferasirox 20 mg/kg/day for 3 months, while the dose was lowered to 4-6 mg/kg/day after 1 month in three patients in response to AEs (mainly gastrointestinal, increased creatinine and rash). Sixteen patients were treated for 82-105 days, two for 112 and 120 days, respectively, and one patient for Baseline levels of LIP and serum ferritin indicated that these patients were iron in deferasirox-treated patients with MDS was previously reported by List et al. 10 In our study, there were no significant changes in serum ferritin or transferrin saturation from baseline to end of study (geometric means). This may be because treatment duration was not long enough or it may indicate that the dose of deferasirox was not optimal.
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Ten of 19 (53%) patients who completed the study experienced an AE, all in the first month of treatment; seven patients (37%) reported more than one AE. A total of 22 AEs were reported: six (27%) infections (four Grade 1, two Grade 2); seven (32%)
gastrointestinal (six Grade 1, one Grade 2); three (14%) bone pain (one Grade 1, one Grade 2, and one unknown); five (23%) skin rash and dyspnea (three Grade 1, one Grade 2 and one unknown); and one (5%) impaired kidney function (Grade 1).
In conclusion, these data highlight the potential of short-term iron chelation therapy to act as an antioxidant by decreasing intra-and extra-cellular toxic iron species, and consequently oxidative stress. In the absence of conclusive prospective data, the value of iron chelation therapy for improving long-term survival of patients with MDS is still unknown. 11, 12 Additional clinical studies are required to fully understand the mechanisms behind the changes in the studied parameters, and to evaluate their correlation with long-term morbidity, mortality and quality of life.
